 BOSTON and ATLANTA , May 10, 2022 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Companys President Chief Executive Officer will present at the upcoming H.C. 